Family

+

−

• No Family data available.

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address
NOVATEK IP LLC	2185 TRACY HALL PARKWAY PROVO UT 84606

International Classification(s)

• E02F:DREDGING; SOIL-SHIFTING

• 2008 Application Filing Year
• E02F Class
• 157 Applications Filed
• 95 Patents Issued To-Date
• 60.51 % Issued To-Date

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
Crockett, Ronald	2185 S. Larsen Pkwy.	74	2274
# of filed Patents : 74 Total Citations : 2274
Hall, David R	2185 S. Larsen Pkwy.	1292	20766
# of filed Patents : 1292 Total Citations : 20766
Tobias, Sigmar	2185 S. Larsen Pkwy.	5	65
# of filed Patents : 5 Total Citations : 65
Wilde, Tyson J	2185 S. Larsen Pkwy.	62	1340
# of filed Patents : 62 Total Citations : 1340

Cited Art Landscape

Load Citation

• No Cited Art to Display

Loading Cited Art Landscape...

Patent Citation Ranking

• 1 Citation Count
• E02F Class

• 8 % this patent is cited more than
• 15 Age

Forward Cite Landscape

Load Citation

• No Forward Cites to Display

Loading Forward Cite Landscape...

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

DATE PUBLISHED	PUBLICATION/PATENT NO.	PUBLICATION TYPE
December 21, 2010	US,7854078,B2   US7854078B2	GRANTED PATENT AS SECOND PUBLICATION
January 21, 2010	US,20100011628,A1   US20100011628A1	FIRST PUBLISHED PATENT APPLICATION

Full Text

US Patent Application No: 2012/0128,649

MODIFIED NON-CYTOTOXIC PROTEASES

---

Abstract

---

The present invention relates to a modified polypeptide comprising a non-cytotoxic protease, a translocation domain, a destructive protease cleavage site and a Targeting Moiety that binds to a Binding Site on a nerve cell, wherein after cleavage of the destructive cleavage site the polypeptide has reduced potency. The destructive cleavage site is recognised and cleaved by a protease present at or in an off-site target cell, and, in one embodiment, the polypeptide is a modified clostridial neurotoxin. The present invention also relates to the use of said polypeptides for treating a range of conditions, and to nucleic acids encoding said polypeptides.

---

 

---

Description

---

Claims

---

Claims data not available

---

Legal Events

• No Legal Status data available.